TESARO (NASDAQ:TSRO) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Saturday.
Other equities research analysts have also recently issued research reports about the company. SunTrust Banks reiterated a “buy” rating and issued a $160.00 price objective on shares of TESARO in a report on Friday, November 10th. Lake Street Capital reiterated a “buy” rating and issued a $143.00 price objective on shares of TESARO in a report on Thursday, November 9th. HC Wainwright restated a “buy” rating on shares of TESARO in a research note on Wednesday, November 8th. Cann restated a “buy” rating and issued a $199.00 target price on shares of TESARO in a research note on Tuesday, November 7th. Finally, Argus set a $154.00 target price on TESARO and gave the company a “buy” rating in a research note on Tuesday, November 28th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. TESARO has a consensus rating of “Hold” and a consensus target price of $149.97.
Shares of TESARO (NASDAQ TSRO) opened at $58.89 on Friday. TESARO has a fifty-two week low of $55.02 and a fifty-two week high of $192.94. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35. The firm has a market capitalization of $3,202.56, a P/E ratio of -6.98 and a beta of 1.25.
Hedge funds have recently bought and sold shares of the stock. Exane Derivatives bought a new position in TESARO during the 3rd quarter valued at approximately $106,000. Toronto Dominion Bank increased its position in TESARO by 244.6% during the 3rd quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,130 shares in the last quarter. Achmea Investment Management B.V. bought a new position in TESARO during the 2nd quarter valued at approximately $234,000. Commonwealth Equity Services Inc bought a new position in TESARO during the 3rd quarter valued at approximately $222,000. Finally, Crossmark Global Holdings Inc. bought a new position in TESARO during the 3rd quarter valued at approximately $230,000.
COPYRIGHT VIOLATION NOTICE: “TESARO (TSRO) Cut to Strong Sell at BidaskClub” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://sportsperspectives.com/2018/02/12/tesaro-tsro-cut-to-strong-sell-at-bidaskclub.html.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.